
Vildagliptin (50mg) + Metformin (500mg)
Active composition
+1 more active ingredient
Vildagliptin inhibits DPP-4, leading to increased levels of incretin hormones, which stimulate insulin secretion and decrease glucagon levels.
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Medical applications
Gliptalex M 50/500 MG Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these agents helps in achieving optimal blood glucose regulation. Gliptalex M is prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve target glycemic levels. It is particularly beneficial for patients who require dual mechanism therapy to control hyperglycemia. The tablet should be administered orally with meals to minimize gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of pancreatitis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Gliptalex M 50/500 MG Tablet offers an effective and well-tolerated option for comprehensive glycemic management in type 2 diabetes.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Gliptalex M 50/500 MG Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Gliptalex M 50/500 MG Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Gliptalex M 50/500 MG Tablet should be used with caution in patients with kidney disease. Dose adjustment of Gliptalex M 50/500 MG Tablet may be needed. Please consult your doctor.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
Gliptalex M 50/500 MG Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Gliptalex M 50/500 MG Tablet

Metformin (500mg) + Vildagliptin (50mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Vildagliptin inhibits DPP-4, leading to increased levels of incretin hormones, which stimulate insulin secretion and decrease glucagon levels.
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Medical applications
Gliptalex M 50/500 MG Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these agents helps in achieving optimal blood glucose regulation. Gliptalex M is prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve target glycemic levels. It is particularly beneficial for patients who require dual mechanism therapy to control hyperglycemia. The tablet should be administered orally with meals to minimize gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of pancreatitis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Gliptalex M 50/500 MG Tablet offers an effective and well-tolerated option for comprehensive glycemic management in type 2 diabetes.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Gliptalex M 50/500 MG Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Gliptalex M 50/500 MG Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Gliptalex M 50/500 MG Tablet should be used with caution in patients with kidney disease. Dose adjustment of Gliptalex M 50/500 MG Tablet may be needed. Please consult your doctor.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
Gliptalex M 50/500 MG Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Gliptalex M 50/500 MG Tablet













